Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease: Analysis of Baseline Factors
Objective: Determine if baseline factors are associated with the apomorphine sublingual film (APL) dose required to achieve FULL “ON.” Background: APL is approved for the…Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease: Characterization of Acute Nausea During Dose Titration
Objective: Characterize acute episodes of nausea experienced by patients with Parkinson’s disease (PD) receiving apomorphine sublingual film (APL) for the on-demand treatment of “OFF” episodes.…Long-Term Safety and Efficacy of Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease: Europe vs North America
Objective: Evaluate long-term safety (LTS), tolerability, and efficacy of apomorphine sublingual film (APL) for on-demand treatment of “OFF” episodes in patients with Parkinson’s disease (PD)…Indirect Comparison of Apomorphine Sublingual Film Versus Levodopa Inhalation Powder for “OFF” Episodes in Parkinson’s Disease
Objective: Conduct a matching-adjusted indirect comparison (MAIC) of the efficacy of apomorphine sublingual film (APL) vs levodopa inhalation powder (CVT-301) for “OFF” episodes in Parkinson’s…Apomorphine infusion before subthalamic deep brain stimulation. A prospective comparative study in the same 20 patients.
Objective: The objetive of this study was to compare the benefit of APO and STN-DBS in aPD in terms of motor (off daily hours, UPDRS…Deterioration in oral health status potentially associated with apomorphine pump initiation: a case report
Objective: To describe the case of a patient with Parkinson’s disease (PD) who suffered from a rapid deterioration of his oral health status following treatment…Impact of device-aided therapies on QoL and Off-time improvement in advanced Parkinson’s Disease patients: Comparative effectiveness results from a Bayesian Network Meta-Analysis
Objective: To compare off-time and QoL changes among APD patients taking LCIG, DBS, CSAI, and BMT at 6 months after therapy initiation. Background: Advanced Parkinson’s…Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease: Impact on Impulse Control Disorders
Objective: Assess impact of apomorphine sublingual film (APL) on impulse control disorders (ICDs) in patients with Parkinson’s disease (PD) and “OFF” episodes. Background: In a…Long-Term Safety and Efficacy of Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease
Objective: Evaluate long-term safety (LTS), tolerability, and efficacy of apomorphine sublingual film (APL) for on-demand treatment of “OFF” episodes in patients with Parkinson’s disease (PD).…Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease: Impact of Concomitant Antiemetics on Nausea and Vomiting
Objective: Analyze the effect of concomitant trimethobenzamide (TMB) on nausea and vomiting rates in patients with Parkinson’s disease (PD) receiving apomorphine sublingual film (APL) for…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 13
- Next Page »